文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

再生障碍性贫血的诊断路径

Approach to the diagnosis of aplastic anemia.
PubMed 文献 · Blood Adv · 2021-01-01

该综述以病例为基础,强调区分获得性与遗传性再生障碍性贫血(AA)对治疗决策的关键性,并汇总了体细胞与胚系分子发现的新数据,讨论其在诊断、预后及治疗指征中的价值与不确定性。

要点

  • 区分获得性与遗传性AA是诊断核心,直接影响免疫抑制治疗与移植选择。
  • 体细胞突变谱可用于预后与治疗指征判断,但证据程度不一。
  • 新认识的胚系综合征扩展了遗传性AA的鉴别范围。

核心结论

  • 确立AA诊断具有挑战性,但对合适管理至关重要,尤其需区分获得性与遗传性形式。

研究设计与样本

  • 采用基于病例的综述格式,强调AA中体细胞与胚系分子发现的新数据及其在诊断中的帮助与否。

主要发现

  • 综述提供了体细胞突变谱的关键细节,并在有证据处说明了其预后与治疗指征。
  • 还概述了新近综合征的胚系细节,反映了临床医生的不确定性领域。

关键数值与推荐

  • 诊断一旦确立,免疫抑制治疗与移植的临床选择正在增多。

临床怎么用

  • 血液学领域需要更新的诊断指南,以确保患者遵循适当的临床路径并保障安全。

局限性

  • 综述反映了临床医生在分子发现解读中的不确定性领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Establishing a diagnosis of aplastic anemia (AA) can be challenging, but it is absolutely critical to appropriate management, especially differentiating between acquired and inherited forms of the disease. The hematology field requires updated diagnostic guidelines to ensure that appropriate clinical pathways are pursued for patients and their safety. There are increasing clinical options for patients with immunosuppressive therapy and transplant once the diagnosis is made. In a case-based format, this review emphasizes the newer data on molecular (somatic and germline) findings in AA and how they are (or are not) helpful during diagnosis. There are key details on somatic mutation profiles and stated evidence where available for prognostic and treatment indications. Germline details of newer syndromes are also outlined, which make this review modern and reflect areas of uncertainty for clinicians.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. Blood Adv. 2021. PMID: 34156438. doi:10.1182/bloodadvances.2021004345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。